Dr Ashish Shetty consultant in pain medicine at the National Hospital for Neurology and Neurosurgery, University College London Hospitals, joins NuroKor. Recognised as one of the few medical experts worldwide to specialise in the field, Dr. Shetty has extensive experience in providing various forms of neuromodulation therapy including non-invasive external neuromodulation, peripheral neuromodulation and spinal cord stimulation therapy.
Having previously held positions as clinical research fellow in pain and neuromodulation at Guy’s and St Thomas’ NHS Foundation Trust and honorary consultant at Great Ormond Street Hospital, Dr. Shetty is passionate about the use of neuromodulation for managing complex neuropathic pain conditions including chronic back, leg and pelvic pain. He also has a special interest in headache, abdominal and pelvic pain.
Dr. Shetty continues in his clinical role as consultant in pain medicine at UCLH, where he has practiced for the past seven years, Dr. Shetty joined NuroKor in December and will be responsible for leading the electroceutical development for pain, clinical study and R&D direction, working closely with the scientific team and various stakeholders.
Dr. Shetty’s support will play a vital role in furthering the growth and expansion of NuroKor as it continues to lead in the bioelectronics space.
Speaking about his appointment, Dr. Shetty said:
“Pain is a complicated, often debilitating medical problem that can have a major impact on the physical and mental wellbeing of a person. Every aspect of my work as a consultant, and as NuroKor’s chief medical officer, is driven by the desire to help patients return to independence and have restored quality of life. Neuromodulation therapy is a key component for my patient’s pain management, and the future application of NuroKor’s technology could see multiple medical fields and their patients benefit.”
In addition to his position at NuroKor, Dr. Shetty will continue with his work as UCLH Consultant, and Honorary Associate Professor at UCL.
Rick Rowan, founder and CEO of NuroKor, added: “We are delighted to welcome Dr. Shetty to the NuroKor team. His wealth of knowledge in pain and neuromodulation will be incredibly useful in bolstering the pioneering work we are already doing in the bioelectronics space.
“When it comes to ensuring that our technology is continually evolving in response to patient demands and the latest advancements in pain management, it is crucial that we are working with the very best clinical talent. Harnessing their skills and expertise allows us to keep innovating, and Dr. Shetty’s experience will be invaluable in NuroKor’s bright future.” - Rick Rowan CEO
UK health-tech startup NuroKor BioElectronics was created by CEO Rick Rowan in 2018, who spotted the potential of bioelectric technology as therapeutic treatments while searching for an alternative to painkillers to treat his 30-year back pain.
Operating across the UK, Norway, US, Australia, New Zealand and Malaysia, the company develops and produces state-of-the-art, wearable technology using peripheral nerve, microcurrent and neuromuscular stimulation, to help manage pain and optimise healing and physical performance.
NuroKor’s users range from more than 50 Olympians and elite athletes, to clinicians and everyday people suffering with an array of conditions - from arthritis to menopause. The bioelectronic technology enables greater autonomy over a person’s own treatment and can reduce the need for medication.
The ‘disruptive’ startup aims to bring about social change, developing natural, personalised bioelectrical medicine that helps people to live better lives and to improve global health.
Today, NuroKor technology is at the forefront of bioelectric medicine, with several research and clinical trial projects running in collaboration with some of the UK’s leading universities.
To find out more, visit: https://nurokor.com